A new study may provide the basis for combating malignant leukemia stem cells.
List view / Grid view
Filter the results
Enzymes are macromolecular biological catalysts. Enzymes accelerate, or catalyse, chemical reactions.
A cellular pathway may reduce side effects and extend immunotherapy duration in patients with the most common form of liver cancer.
A research team have developed a new CRISPR platform called RESCUE (RNA Editing for Specific C to U Exchange).
Researchers have used machine learning to discover that the two most widespread DNA structures cause genome mutations that lead to cancer.
A study has shown that deactivating an enzyme linked to ceramides caused obese mice to improve their metabolic health, indicating a drug target.
A study has discovered that a biomarker associated with pancreatitis is involved in its development to pancreatic cancer.
Redundancies have been discovered in the biochemical signalling pathways of immune cells which could impact cancer immunotherapy.
Researchers have found an enzyme and its counterpart which inhibit T-cells from attacking tumour cells.
New research could lead to novel treatments for autoimmune disorders and sheds light on the causes of autoimmunity.
Columbia University discovery could be a major step in developing therapies for cancer, controlling cholesterol...
New approach restores epithelial function in diarrhoea and inflammatory bowel disease models...
Researchers in the US have discovered how a gene involved in regulating hormone receptors, GREB1, may contribute to drug resistance in some prostate cancer patients.
Series of molecules may provide more reliable relief with fewer side effects...
With breakthroughs in molecular engineering and antibody humanisation, monoclonal antibodies (mAb) are one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications including cancer, cardiovascular disease, autoimmune disorders and infectious disease. Most therapeutic antibody candidates are initially generated using hybridoma technology or primary B-cell screening after antigen immunisation.